Tezepelumab : A Potential New Biological Therapy for Severe Refractory Asthma
Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of cellular and molecular pathways leading to type 2 (T2-high) airway inflammation. Released from airway epithelial cells upon tissue damage induced by several noxious agents including allergens, viruses, bacteria, and airborne pollutants, TSLP activates dendritic cells and group 2 innate lymphoid cells involved in the pathobiology of T2-high asthma. Tezepelumab is a fully human monoclonal antibody that binds to TSLP, thereby preventing its interaction with the TSLP receptor complex. Preliminary results of randomized clinical trials suggest that tezepelumab is characterized by a good safety and efficacy profile in patients with severe, uncontrolled asthma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 22(2021), 9 vom: 22. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pelaia, Corrado [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alarmins |
|---|
| Anmerkungen: |
Date Completed 28.05.2021 Date Revised 28.05.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms22094369 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324753217 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324753217 | ||
| 003 | DE-627 | ||
| 005 | 20231225191004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms22094369 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1082.xml |
| 035 | |a (DE-627)NLM324753217 | ||
| 035 | |a (NLM)33922072 | ||
| 035 | |a (PII)4369 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pelaia, Corrado |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tezepelumab |b A Potential New Biological Therapy for Severe Refractory Asthma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.05.2021 | ||
| 500 | |a Date Revised 28.05.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of cellular and molecular pathways leading to type 2 (T2-high) airway inflammation. Released from airway epithelial cells upon tissue damage induced by several noxious agents including allergens, viruses, bacteria, and airborne pollutants, TSLP activates dendritic cells and group 2 innate lymphoid cells involved in the pathobiology of T2-high asthma. Tezepelumab is a fully human monoclonal antibody that binds to TSLP, thereby preventing its interaction with the TSLP receptor complex. Preliminary results of randomized clinical trials suggest that tezepelumab is characterized by a good safety and efficacy profile in patients with severe, uncontrolled asthma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a TSLP | |
| 650 | 4 | |a alarmins | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a tezepelumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tezepelumab |2 NLM | |
| 650 | 7 | |a RJ1IW3B4QX |2 NLM | |
| 700 | 1 | |a Pelaia, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Crimi, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Maglio, Angelantonio |e verfasserin |4 aut | |
| 700 | 1 | |a Gallelli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Terracciano, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Vatrella, Alessandro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 22(2021), 9 vom: 22. Apr. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:9 |g day:22 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms22094369 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 9 |b 22 |c 04 | ||